TabletsTablets
Schedule H (Prescription Required)AntimalarialsCode: 375

Quinine Sulphate Tablets 300 mg

Generic Formulation:Quinine Sulphate Tablets IP 300 mg
Pack Size:10's
Common Commercial Brand Equivalents:Market reference only
Jan Aushadhi MRP
₹30.4
Brand Estimate*
₹155.3
Estimated Savings:₹124.90 (80% saved)
Find a Kendra Near You
*Statutory price across 21,118 listed Kendras
Clinical InformationReport Error

Clinical Overview

Quinine Sulphate is a cinchona alkaloid schizontocidal antimalarial agent. It acts primarily on the asexual erythrocytic forms of all Plasmodium species by interfering with hemozoin synthesis and parasite digestion of hemoglobin. Indicated for uncomplicated and severe chloroquine-resistant Plasmodium falciparum malaria and nocturnal leg cramps (unlabeled, restricted due to toxicity).

Active Pharmaceutical Ingredients

AI-assistedClinical summary synthesized from pharmacopoeial references (CDSCO, WHO EML, IP/BP/USP). Not clinician-reviewed. Drug code 375.Report inaccuracy

Usage Guidelines

Take orally with food or a full glass of water to minimize gastric irritation. Do not crush or chew tablets. Strictly follow the 7-day course prescribed by your physician.

General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.

Possible Side Effects

Common: "Cinchonism" (tinnitus, high-frequency hearing loss, headache, nausea, blurred vision, dizziness, flushing). Rare/Severe: Severe hypoglycemia (via stimulation of pancreatic beta-cell insulin secretion), QT prolongation, Blackwater fever (massive intravascular hemolysis and renal failure), thrombocytopenic purpura, and blindness.

*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.

Precautions & Warnings

Contraindicated in patients with myasthenia gravis, optic neuritis, G6PD deficiency, or congenital QT prolongation. Monitor blood glucose levels frequently due to high risk of hyperinsulinemic hypoglycemia, especially in pregnant women.

Schedule H (Prescription Required)

This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.

Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.